Biopharmas raising money in public or private financings.

Med-tech firms raising money in public or private financings.

Med-tech firms raising money in public or private financings.

Biopharmas raising money in public or private financings.

HONG KONG – U.S.-based biotech firm Egenesis Inc., headquartered in Cambridge, Mass., has received $100 million through a series B funding round for the development of safe and effective human-compatible organs through gene editing.

Med-tech firms raising money in public or private financings.

Biopharmas raising money in public or private financings.

Biopharmas raising money in public or private financings.

Avidity Biosciences Inc. CEO Sarah Boyce told BioWorld it's "a little too soon" to say when the company's lead program in myotonic dystrophy type I might reach the clinic, but the firm's $100 million series C financing will help with that effort and the portfolio in rare muscle diseases, as the antibody-oligonucleotide conjugate (AOC) platform undergoes further development.